New Dawn Bio Secures €2.1M to Develop Deforestation-Free Cultured Wood
  • News
  • Europe

New Dawn Bio Secures €2.1 Million to Develop Deforestation-Free Cultured Wood

The CapitalT-led round will help scale its technology for growing wood from tree stem cells.

6/4/2026
Ghita Khalfaoui
Back to News

Dutch deep-tech startup New Dawn Bio has secured €2.1 million in an oversubscribed pre-seed funding round to pioneer the world's first cultured wood. Led by CapitalT, the investment will accelerate technology that grows premium timber from tree stem cells in bioreactors. This innovative approach aims to revolutionize the materials industry by producing wood without logging and addressing critical environmental challenges.


A New Frontier in Wood Production

New Dawn Bio's process begins by harvesting stem cells from trees and multiplying them within bioreactors. The cells receive biological signals that guide them to harden into wood tissue, just as they would inside a living trunk. This method allows the company to grow wood directly into the exact shape of the final product, bypassing traditional manufacturing.

The technology boasts a production speed up to 10,000 times faster than conventional forestry, growing wood in days instead of decades. By eliminating the need to cut rectangular planks from round logs, the process eradicates significant material waste. This efficiency could reduce a customer's cost of goods sold by as much as 80 percent.

Addressing Deforestation and Market Needs

The innovation arrives at a critical time, with the world losing 5.3 million hectares of tropical forest annually. Deforestation contributes significantly to global carbon emissions and threatens biodiversity, creating immense pressure on traditional supply chains. New Dawn Bio's solution directly targets this issue by offering a sustainable alternative to logging for a massive global market.

Strategic Investment to Fuel Growth

The €2.1 million funding round was led by CapitalT, with participation from Norrsken Evolve, Ontdekkers Group, and angel investors. This capital is earmarked for advancing product development and scaling the technology from small samples to tabletop-scale production. The investment underscores investor confidence in the company's deep-tech approach to a global problem.

A key focus for the funding will be expanding the company's interdisciplinary research and development team. New Dawn Bio is assembling experts in cell biology, materials engineering, and process engineering to refine its proprietary methods. This strategic team growth is essential for turning the scientific breakthrough into a commercially viable product.

A Vision for Sustainable Materials

Founded by CEO Tom Clement and COO Kianti Figler, New Dawn Bio aims to fundamentally change a millennia-old process. Clement stated, "For the first time in history, we can now grow pre-shaped premium wood." This vision reflects a shift towards solving material science challenges with deep biological engineering to create a usable industrial product.

Janneke Niessen, Founding Partner at CapitalT, praised the startup as an impact-driven company tackling an overlooked problem. She noted that cultured wood has the potential to transform entire supply chains while making a meaningful contribution to the planet. This endorsement highlights the dual promise of commercial returns and positive environmental impact that attracted investors.

Navigating the Competitive Landscape

While other companies are exploring wood alternatives, New Dawn Bio's approach is distinct. Unlike competitors focusing on wood-like substitutes from mycelium or extracts, the Dutch startup is dedicated to growing actual wood tissue. This focus on creating structurally identical, premium timber in its final form sets it apart in the emerging field.


New Dawn Bio's successful pre-seed funding marks a significant step toward a future where premium wood can be grown sustainably and efficiently. The company's technology offers a compelling solution to the environmental toll of deforestation while meeting the demands of a global market. The primary challenge now lies in scaling this groundbreaking process from the laboratory to an industrial scale.